PALO ALTO, Calif.--(BUSINESS WIRE)--Silicon Valley-based Medable Inc. continues to disrupt clinical trials with the first telemedicine solution, specifically designed for clinical trials. Medable’s Trial-Fit Telemedicine has been developed and designed to address critical trial barriers of low patient retention and lack of access.
Medable has become known as a pioneer in data-driven digital trials, with the first global digital trials solution. Medable’s Trial-Fit Telemedicine enables sites all over the world to conduct secure, HIPAA-compliant video consultations with clinical study participants in an integrated eCOA solution.
“Medable is on a mission to get effective therapies to patients faster. Medable is building a globally connected research ecosystem in which every person in the world has the opportunity to benefit from cutting edge research. Telemedicine is an essential enabling technology in our mission to serve patients all over the world.” Dr. Michelle Longmire, CEO and co-founder at Medable.
Medable telemedicine is the only integrated, multi-language and globally supported site and patient telemedicine experience that enables clinicians to remotely care for, monitor and manage study participants in any location. “Increasing access to trials is a top priority for Medable. 50% of trials do not achieve planned enrollment strategies… we are working to fix that,” Dr. Longmire continued.
The company’s eClinical platform uniquely enables data-driven digital trials by leveraging big data and analytics to identify patients and connect them with trials powered by Medable eCOA solutions. As the market leader in digital trials, Medable now provides a unique telemedicine solution that enables life science, biotech and medical device companies to expand a study’s geographic reach for patient enrollment.
“Digital technologies have the ability to revolutionize trials. Telemedicine can improve access, enrollment, and retention and is central to our strategy to reduce trial time, improve trial diversity, and enable an era of personalized medicine, which will require much broader study access and participation. Telemedicine is an important part of our strategy to make trials more representative and to radically reduce the time and cost, with the goal of getting effective therapies to patients faster.” Dr. Longmire added.
Medable will introduce and launch this new telemedicine offering at this year’s Drug Information Association (DIA) global annual meeting in San Diego on June 23-27, 2019. Visit us at Exhibit #2331 to learn more.
Medable is a privately held, venture-backed company headquartered in Palo Alto, California. Medable’s mission is to dramatically reduce the time of therapeutic development to market and get effective therapies to patients faster. Medable is pioneering a new category of life science technologies that replace the stagnant and siloed data of traditional ePRO, eCOA, EDC, and eSource with an intelligent and unified end-to-end (E2E) platform for clinical trial execution. Medable’s E2E platform connects patients, sites, CRO’s and sponsors to work together as a connected and empowered team in clinical research.
For more information, visit www.medable.com and follow Medable on Twitter: @Medableinc